GAIA BioMedicine Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $13.3M

  • Investors
  • 10

GAIA BioMedicine General Information

Description

Operator of a biopharmaceutical company intended to deliver cancer immuno-cell therapy. The company offers antibody-anchoring peptide technology, tumor infiltration, and off-the-shelf cell formulations that help to eliminate solid tumors without genetic modification, enabling patients to fight intractable diseases using the power of genes and the immune system.

Contact Information

Website
www.gaia-biomed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 403, Collaborative Research Station II Kyushu University Hospital Campus
  • 3-1-1 Maidashi, Higashi-ku
  • Fukuoka, 812-8582
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 403, Collaborative Research Station II Kyushu University Hospital Campus
  • 3-1-1 Maidashi, Higashi-ku
  • Fukuoka, 812-8582
  • Japan
+81

GAIA BioMedicine Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GAIA BioMedicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) 11-Jul-2025 $13.3M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C) 30-May-2023 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 21-Sep-2021 Completed Clinical Trials - Phase 1
2. Grant 28-May-2021 $917K $5.95M Completed Clinical Trials - Phase 1
1. Later Stage VC (Series A) 15-Jan-2020 $5.95M $5.95M Completed Clinical Trials - Phase 1
To view GAIA BioMedicine’s complete valuation and funding history, request access »

GAIA BioMedicine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class D Preferred
Class C Preferred
Class B2 Preferred
Class B Preferred 25,261 $131.06 $131.06 1x $131.06 7.77%
Class A Preferred 97,163 $72.43 $72.43 1x $72.43 29.89%
To view GAIA BioMedicine’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

GAIA BioMedicine Patents

  • 130

    Total Documents Applications and Grants

  • Total Patents Families

  • 53

    Granted

  • 41

    Pending

  • Expiring in next 12 mo

GAIA BioMedicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025247105-A1 Membrane-anchored il-2 and use thereof Pending 29-Mar-2024
WO-2025206249-A1 Membrane-anchored il-2 and use thereof Pending 29-Mar-2024
GB-2645082-A Cell population production method Pending 21-Jul-2023
WO-2025022372-A1 Cell population production method Inactive 21-Jul-2023
AU-2024298429-A1 Method for producing cell population Pending 21-Jul-2023 C12N5/06
To view GAIA BioMedicine’s complete patent history, request access »

GAIA BioMedicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GAIA BioMedicine Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
JIC Venture Growth Investments Venture Capital Minority
UntroD Venture Capital Minority
CEJ Capital Corporate Venture Capital Minority
Hisamitsu Pharmaceutical Corporation Minority
SBI Investment Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

GAIA BioMedicine FAQs

  • When was GAIA BioMedicine founded?

    GAIA BioMedicine was founded in 2015.

  • Where is GAIA BioMedicine headquartered?

    GAIA BioMedicine is headquartered in Fukuoka, Japan.

  • What is the size of GAIA BioMedicine?

    GAIA BioMedicine has 13 total employees.

  • What industry is GAIA BioMedicine in?

    GAIA BioMedicine’s primary industry is Drug Discovery.

  • Is GAIA BioMedicine a private or public company?

    GAIA BioMedicine is a Private company.

  • What is the current valuation of GAIA BioMedicine?

    The current valuation of GAIA BioMedicine is .

  • What is GAIA BioMedicine’s current revenue?

    The current revenue for GAIA BioMedicine is .

  • How much funding has GAIA BioMedicine raised over time?

    GAIA BioMedicine has raised $36.2M.

  • Who are GAIA BioMedicine’s investors?

    JIC Venture Growth Investments, UntroD, CEJ Capital, Hisamitsu Pharmaceutical, and SBI Investment are 5 of 10 investors who have invested in GAIA BioMedicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process